$4.08
0.37% yesterday
Nasdaq, May 01, 10:00 pm CET
ISIN
US3722791098
Symbol
GNFT
Sector
Industry

Genfit SA Sponsored ADR Stock price

$4.08
+0.56 15.77% 1M
-1.80 30.61% 6M
+0.37 9.83% YTD
+0.64 18.63% 1Y
+0.48 13.33% 3Y
-17.79 81.34% 5Y
-16.24 79.92% 10Y
Nasdaq, Closing price Thu, May 01 2025
-0.02 0.37%
ISIN
US3722791098
Symbol
GNFT
Sector
Industry

Key metrics

Market capitalization $203.45m
Enterprise Value $183.10m
P/E (TTM) P/E ratio 129.52
EV/FCF (TTM) EV/FCF 11.90
EV/Sales (TTM) EV/Sales 2.53
P/S ratio (TTM) P/S ratio 2.81
P/B ratio (TTM) P/B ratio 1.96
Revenue growth (TTM) Revenue growth 134.52%
Revenue (TTM) Revenue $72.43m
EBIT (operating result TTM) EBIT $-2.70m
Free Cash Flow (TTM) Free Cash Flow $15.39m
EPS (TTM) EPS $0.03
P/E forward 2.95
P/S forward 1.45
EV/Sales forward 1.31
Short interest 0.13%
Show more

Is Genfit SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,792 stocks worldwide.

Genfit SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Genfit SA Sponsored ADR forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Genfit SA Sponsored ADR forecast:

Buy
100%

Financial data from Genfit SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
72 72
135% 135%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
2% 2%
26%
- Research and Development Expense 53 53
8% 8%
73%
-0.83 -0.83
98% 98%
-1%
- Depreciation and Amortization 1.86 1.86
18% 18%
3%
EBIT (Operating Income) EBIT -2.70 -2.70
93% 93%
-4%
Net Profit 1.58 1.58
105% 105%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Genfit SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genfit SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
3 days ago
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marches financiers (AMF ; filing n° D.25-0331) and ...
Neutral
GlobeNewsWire
4 days ago
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen will be presenting data from its late-breaking abstract on elafibranor, highlighting favorable safety profile and sig...
Neutral
GlobeNewsWire
8 days ago
Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2024. A summary of the consolidated financial statements is included below.
More Genfit SA Sponsored ADR News

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

Head office France
CEO Pascal Prigent
Founded 1999
Website www.genfit.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today